Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
World Journal of Surgical Oncology
Published in: World Journal of Surgical Oncology 1/2017

Open Access 01-12-2017 | Research

Expression and clinicopathologic significance of TUFM and p53 for the normal–adenoma–carcinoma sequence in colorectal epithelia

Authors: Hong-Qing Xi, Ke-Cheng Zhang, Ji-Yang Li, Jian-Xin Cui, Po Zhao, Lin Chen

Published in: World Journal of Surgical Oncology | Issue 1/2017

Login to get access

Abstract

Background

Evidence indicates that most cases of colorectal carcinoma (CRC) develop from adenoma. A previous study demonstrated that mitochondrial Tu translation elongation factor (TUFM) might serve as an independent prognostic factor for colorectal cancer. However, the expression and function of TUFM in the normal–adenoma–cancer sequence have not been reported. In this study, we investigated the clinicopathologic significance of TUFM and p53 expression for the normal–adenoma–carcinoma sequence in colorectal epithelia and evaluated the roles of TUFM during the progression of colorectal tumors.

Methods

Paraffin-embedded specimens from 261 colorectal normal mucosa samples, 157 adenomas, and 104 early carcinomas were analyzed for TUFM and p53 expression by immunohistochemistry.

Results

Expression of TUFM and p53 was significantly increased during the colorectal normal–adenoma–carcinoma sequence (all P < 0.05). The expression of TUFM and p53 was associated with histologic type of adenomas (P = 0.028; P = 0.001) and grade of dysplasia (all P = 0.001). Expression of TUFM was positively correlated with that of p53 (r = 0.319, P = 0.001).

Conclusions

Upregulated TUFM expression may play an important role in the transformation from colorectal normal mucosa to carcinoma through adenoma. Combined immunohistochemical detection of TUFM and p53 may be useful for evaluating the biological behavior of colorectal adenoma.
Literature
1.
Morson BC. Evolution of cancer of the colon and rectum. Proc Inst Med Chic. 1974;30:145–8.PubMed
2.
Muto T, Bussey HJ, Morson BC. The evolution of cancer of the colon and rectum. Cancer. 1975;36:2251–70.CrossRefPubMed
3.
Mulder JW, Offerhaus GJ, de Feyter EP, Floyd JJ, Kern SE, Vogelstein B, Hamilton SR. The relationship of quantitative nuclear morphology to molecular genetic alterations in the adenoma-carcinoma sequence of the large bowel. Am J Pathol. 1992;141:797–804.PubMedPubMedCentral
4.
Parmeggiani A, Nissen P. Elongation factor Tu-targeted antibiotics: four different structures, two mechanisms of action. FEBS Lett. 2006;580:4576–81.CrossRefPubMed
5.
Spremulli LL, Coursey A, Navratil T, Hunter SE. Initiation and elongation factors in mammalian mitochondrial protein biosynthesis. Prog Nucleic Acid Res Mol Biol. 2004;77:211–61.CrossRefPubMed
6.
Wells J, Henkler F, Leversha M, Koshy R. A mitochondrial elongation factor-like protein is over-expressed in tumours and differentially expressed in normal tissues. FEBS Lett. 1995;358:119–25.CrossRefPubMed
7.
Gross SR, Kinzy TG. Translation elongation factor 1A is essential for regulation of the actin cytoskeleton and cell morphology. Nat Struct Mol Biol. 2005;12:772–8.CrossRefPubMed
8.
Zipfel C, Kunze G, Chinchilla D, Caniard A, Jones JD, Boller T, Felix G. Perception of the bacterial PAMP EF-Tu by the receptor EFR restricts Agrobacterium-mediated transformation. Cell. 2006;125:749–60.CrossRefPubMed
9.
10.
Li LS, Kim H, Rhee H, Kim SH, Shin DH, Chung KY, Park KS, Paik YK, Chang J, Kim H. Proteomic analysis distinguishes basaloid carcinoma as a distinct subtype of nonsmall cell lung carcinoma. Proteomics. 2004;4:3394–400.CrossRefPubMed
11.
Qi Y, Chiu JF, Wang L, Kwong DL, He QY. Comparative proteomic analysis of esophageal squamous cell carcinoma. Proteomics. 2005;5:2960–71.CrossRefPubMed
12.
Kim HK, Park WS, Kang SH, Warda M, Kim N, Ko JH, Prince Ael B, Han J. Mitochondrial alterations in human gastric carcinoma cell line. Am J Physiol Cell Physiol. 2007;293:C761–771.CrossRefPubMed
13.
Srisomsap C, Sawangareetrakul P, Subhasitanont P, Panichakul T, Keeratichamroen S, Lirdprapamongkol K, Chokchaichamnankit D, Sirisinha S, Svasti J. Proteomic analysis of cholangiocarcinoma cell line. Proteomics. 2004;4:1135–44.CrossRefPubMed
14.
Grant AG, Flomen RM, Tizard ML, Grant DA. Differential screening of a human pancreatic adenocarcinoma lambda gt11 expression library has identified increased transcription of elongation factor EF-1 alpha in tumour cells. Int J Cancer. 1992;50:740–5.CrossRefPubMed
15.
He K, Guo X, Liu Y, Li J, Hu Y, Wang D, Song J. TUFM downregulation induces epithelial-mesenchymal transition and invasion in lung cancer cells via a mechanism involving AMPK-GSK3beta signaling. Cell Mol Life Sci. 2016;73:2105–21.CrossRefPubMed
16.
Shi H, Hayes M, Kirana C, Miller R, Keating J, Macartney-Coxson D, Stubbs R. TUFM is a potential new prognostic indicator for colorectal carcinoma. Pathology. 2012;44:506–12.CrossRefPubMed
17.
Bond JH. Polyp guideline: diagnosis, treatment, and surveillance for patients with colorectal polyps. Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol. 2000;95:3053–63.CrossRefPubMed
18.
Crawford LV, Pim DC, Bulbrook RD. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer. 1982;30:403–8.CrossRefPubMed
19.
Donehower LA, Bradley A. The tumor suppressor p53. Biochim Biophys Acta. 1993;1155:181–205.PubMed
20.
Halaby MJ, Yang DQ. p53 translational control: a new facet of p53 regulation and its implication for tumorigenesis and cancer therapeutics. Gene. 2007;395:1–7.CrossRefPubMed
21.
Millau JF, Bastien N, Drouin R. P53 transcriptional activities: a general overview and some thoughts. Mutat Res. 2009;681:118–33.CrossRefPubMed
22.
Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253:49–53.CrossRefPubMed
23.
Hamelin R, Laurent-Puig P, Olschwang S, Jego N, Asselain B, Remvikos Y, Girodet J, Salmon RJ, Thomas G. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology. 1994;106:42–8.CrossRefPubMed
24.
Yamaguchi A, Kurosaka Y, Fushida S, Kanno M, Yonemura Y, Miwa K, Miyazaki I. Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis. Cancer. 1992;70:2778–84.CrossRefPubMed
25.
26.
Lotem J, Sachs L. Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells. Cell Growth Differ. 1993;4:41–7.PubMed
27.
Sui X, Zhu J, Tang H, Wang C, Zhou J, Han W, Wang X, Fang Y, Xu Y, Li D, et al. p53 controls colorectal cancer cell invasion by inhibiting the NF-kappaB-mediated activation of Fascin. Oncotarget. 2015;6:22869–79.CrossRefPubMedPubMedCentral
28.
Iwamuro M, Kawai Y, Matsumoto T, Uda M, Okada H. Serum anti-p53 antibody as a tumour marker for colorectal cancer screening. Ecancermedicalscience. 2015;9:560.CrossRefPubMedPubMedCentral
29.
Mulder JW, Wielenga VJ, Pals ST, Offerhaus GJ. p53 and CD44 as clinical markers of tumour progression in colorectal carcinogenesis. Histochem J. 1997;29:439–52.CrossRefPubMed
30.
Xu C, Wang J, Li J, Fang R. Expression of elongation factor (EF)-Tu is correlated with prognosis of gastric adenocarcinomas. Int J Mol Sci. 2011;12:6645–55.CrossRefPubMedPubMedCentral
31.
Matsubara J, Yamada Y, Nakajima TE, Kato K, Hamaguchi T, Shirao K, Shimada Y, Shimoda T. Clinical significance of insulin-like growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer. Oncology. 2008;74:76–83.CrossRefPubMed
32.
Carneiro FP, Ramalho LN, Britto-Garcia S, Ribeiro-Silva A, Zucoloto S. Immunohistochemical expression of p16, p53, and p63 in colorectal adenomas and adenocarcinomas. Dis Colon Rectum. 2006;49:588–94.CrossRefPubMed
33.
Sanchez-Arago M, Chamorro M, Cuezva JM. Selection of cancer cells with repressed mitochondria triggers colon cancer progression. Carcinogenesis. 2010;31:567–76.CrossRefPubMed
34.
Saleh HA, Jackson H, Banerjee M. Immunohistochemical expression of bcl-2 and p53 oncoproteins: correlation with Ki67 proliferation index and prognostic histopathologic parameters in colorectal neoplasia. Appl Immunohistochem Mol Morphol. 2000;8:175–82.PubMed
35.
36.
Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol. 1988;8:531–9.CrossRefPubMedPubMedCentral
37.
38.
Goussia AC, Ioachim E, Agnantis NJ, Mahera M, Tsianos EV. Bcl-2 expression in colorectal tumours. Correlation with p53, mdm-2, Rb proteins and proliferation indices. Histol Histopathol. 2000;15:667–72.PubMed
39.
Hao XP, Ilyas M, Talbot IC. Expression of Bcl-2 and p53 in the colorectal adenoma-carcinoma sequence. Pathobiology. 1997;65:140–5.CrossRefPubMed
40.
Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I, Seeff LC, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544–73.CrossRefPubMedPubMedCentral
Metadata
Title
Expression and clinicopathologic significance of TUFM and p53 for the normal–adenoma–carcinoma sequence in colorectal epithelia
Authors
Hong-Qing Xi
Ke-Cheng Zhang
Ji-Yang Li
Jian-Xin Cui
Po Zhao
Lin Chen
Publication date
01-12-2017
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2017
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-017-1111-x

Other articles of this Issue 1/2017

World Journal of Surgical Oncology 1/2017 Go to the issue

Case report

Lower abdominal gossypiboma mimics ovarian teratoma: a case report and review of the literature

Research

Preoperative embolization in patients with metastatic spinal cord compression: mandatory or optional?

Case Report

Low-grade appendiceal mucinous neoplasm and endometriosis of the appendix

Research

Better survival after breast-conserving therapy compared to mastectomy when axillary node status is positive in early-stage breast cancer: a registry-based follow-up study of 6387 Norwegian women participating in screening, primarily operated between 1998 and 2009

Review

Feasibility and diagnostic performance of dual-tracer-guided sentinel lymph node biopsy in cT1-2N0M0 gastric cancer: a systematic review and meta-analysis of diagnostic studies

Research

The effects of chemoradiotherapy on recurrence and survival in locally advanced rectal cancers with curative total mesorectal excision: a prospective, nonrandomized study